Filter Results:
(22)
Show Results For
- All HBS Web
(115)
- Faculty Publications (22)
Show Results For
- All HBS Web
(115)
- Faculty Publications (22)
diabetes →
Page 1 of 22
Results →
- August 2024
- Case
Novo Nordisk Foundation
By: Debora L. Spar and Julia Comeau
In 2024, Novo Nordisk A/S was one of the most profitable firms in the world, thanks largely to just two GLP-1-based drugs, Ozempic and Wegovy. Unusually, this incredibly profitable firm was controlled not by individual private shareholders, but by a non-profit... View Details
- April 2024 (Revised July 2024)
- Case
Market Dynamics and Moral Dilemmas: Novo Nordisk’s Weight-Loss Drugs
By: Joseph L. Badaracco, Tom Quinn and John Schultz
Danish pharmaceutical company Novo Nordisk was owned by a charitable foundation, and since its founding in the 1920s had focused on producing insulin to treat diabetes. In 2017, however, it released Ozempic, a diabetes treatment with the revolutionary side effect of... View Details
Keywords: Cost vs Benefits; Decisions; Judgments; Values and Beliefs; Global Strategy; Health Care and Treatment; Patents; Growth and Development Strategy; Growth Management; Product Positioning; Supply and Industry; Supply Chain; Corporate Social Responsibility and Impact; Mission and Purpose; Philanthropy and Charitable Giving; Opportunities; Social Issues; Equality and Inequality; Pharmaceutical Industry; Health Industry; Denmark; United States; Europe; China; India; Middle East; North Africa
Badaracco, Joseph L., Tom Quinn, and John Schultz. "Market Dynamics and Moral Dilemmas: Novo Nordisk’s Weight-Loss Drugs." Harvard Business School Case 324-114, April 2024. (Revised July 2024.)
- October 2023
- Case
Vida Health: Transforming Chronic Disease Treatment
By: William Sahlman and Nicole Tempest Keller
San Francisco based Vida Health, founded by Stephanie Tilenius, former vice president of Commerce and Payments at Google, was a B2B digital health startup focused on the treatment of cardiometabolic conditions, such as diabetes and obesity. Its innovative digital... View Details
Keywords: Corporate Strategy; Growth and Development Strategy; Demand and Consumers; Health Care and Treatment; Product Marketing; Risk and Uncertainty; Technological Innovation; Health Industry; Technology Industry; United States; California; San Francisco
Sahlman, William, and Nicole Tempest Keller. "Vida Health: Transforming Chronic Disease Treatment." Harvard Business School Case 824-001, October 2023.
- July 2023
- Case
DayTwo: Going to Market with Gut Microbiome (Abridged)
By: Ayelet Israeli
DayTwo is a young Israeli startup that applies research on the gut microbiome and machine learning algorithms to deliver personalized nutritional recommendations to its users in order to minimize blood sugar spikes after meals. After a first year of trial rollout in... View Details
Keywords: Business Startups; AI and Machine Learning; Nutrition; Market Entry and Exit; Product Marketing; Distribution Channels
Israeli, Ayelet. "DayTwo: Going to Market with Gut Microbiome (Abridged)." Harvard Business School Case 524-015, July 2023.
- January 2023
- Case
Vertex and the Cure for Type 1 Diabetes
By: Amitabh Chandra, William J Anderson and Silvia Mare
Keywords: Biotechnology Industry
- January 2021
- Case
Value-Based Insurance Design at Onex
By: Joshua Schwartzstein, Amitabh Chandra and Amram Migdal
The operating executives of Health and Benefits for Onex Partners, Megan Jackson Frye and Sam Camens, faced a challenge: Healthcare costs for employees of Onex’s portfolio companies were continuing to rise above the consumer price index, reflecting broader trends... View Details
Keywords: Decision Making; Cost vs Benefits; Decision Choices and Conditions; Decisions; Finance; Behavioral Finance; Insurance; Health; Health Care and Treatment; Human Resources; Compensation and Benefits; Markets; Demand and Consumers; Consumer Behavior; Social Psychology; Behavior; Interests; Motivation and Incentives; Perception; Health Industry; Insurance Industry; North America; United States
Schwartzstein, Joshua, Amitabh Chandra, and Amram Migdal. "Value-Based Insurance Design at Onex." Harvard Business School Case 921-023, January 2021.
- November 2020
- Teaching Note
DayTwo: Going to Market with Gut Microbiome
By: Ayelet Israeli
Teaching Note for HBS Case No. 519-010. DayTwo is a young Israeli startup that applies research on the gut microbiome and machine learning algorithms to deliver personalized nutritional recommendations to its users in order to minimize blood sugar spikes after meals.... View Details
Keywords: Start-up Growth; Startup; Positioning; Targeting; Go To Market Strategy; B2B Vs. B2C; B2B2C; Health & Wellness; AI; Machine Learning; Female Ceo; Female Protagonist; Science-based; Science And Technology Studies; Ecommerce; Applications; DTC; Direct To Consumer Marketing; US Health Care; "USA,"; Innovation; Pricing; Business Growth; Segmentation; Distribution Channels; Growth and Development Strategy; Business Startups; Science-Based Business; Health; Innovation and Invention; Marketing; Information Technology; Business Growth and Maturation; E-commerce; Applications and Software; Health Industry; Technology Industry; Insurance Industry; Information Technology Industry; Food and Beverage Industry; Israel; United States
- August 2020
- Article
Do Physician Incentives Increase Patient Medication Adherence?
By: Edward Kong, John Beshears, David Laibson, Brigitte Madrian, Kevin Volpp, George Loewenstein, Jonathan Kolstad and James J. Choi
We conducted a randomized experiment (911 primary care practices and 8,935 nonadherent patients) to test the effect of paying physicians for increasing patient medication adherence in three drug classes: diabetes medication, antihypertensives, and statins. We measured... View Details
Keywords: Health Economics; Medication Adherence; Physician Payment Incentives; Primary Care; Quality Improvement; Health Care and Treatment; Motivation and Incentives; Behavior
Kong, Edward, John Beshears, David Laibson, Brigitte Madrian, Kevin Volpp, George Loewenstein, Jonathan Kolstad, and James J. Choi. "Do Physician Incentives Increase Patient Medication Adherence?" Health Services Research 55, no. 4 (August 2020): 503–511.
- Article
Navy Medicine Introduces Value-Based Health Care
By: Alee Hernandez, Robert S. Kaplan, Mary L. Witkowski, C. Forrest Faison III and Michael E. Porter
In 2016 the newly appointed surgeon general of the Navy launched a value-based health care pilot project at Naval Hospital Jacksonville to explore whether multidisciplinary care teams (known as integrated practice units, or IPUs) and measurement of outcomes could... View Details
Hernandez, Alee, Robert S. Kaplan, Mary L. Witkowski, C. Forrest Faison III, and Michael E. Porter. "Navy Medicine Introduces Value-Based Health Care." Health Affairs 38, no. 8 (August 2019): 1393–1400.
- March 2019
- Case
DayTwo: Going to Market with Gut Microbiome
By: Ayelet Israeli and David Lane
DayTwo is a young Israeli startup that applies research on the gut microbiome and machine learning algorithms to deliver personalized nutritional recommendations to its users in order to minimize blood sugar spikes after meals. After a first year of trial rollout in... View Details
Keywords: Start-up Growth; Startup; Positioning; Targeting; Go To Market Strategy; B2B2C; B2B Vs. B2C; Health & Wellness; AI; Machine Learning; Female Ceo; Female Protagonist; Science-based; Science And Technology Studies; Ecommerce; Applications; DTC; Direct To Consumer Marketing; US Health Care; "USA,"; Innovation; Pricing; Business Growth; Segmentation; Distribution Channels; Growth and Development Strategy; Business Startups; Science-Based Business; Health; Innovation and Invention; Marketing; Information Technology; Business Growth and Maturation; E-commerce; Applications and Software; Health Industry; Technology Industry; Insurance Industry; Information Technology Industry; Food and Beverage Industry; Israel; United States
Israeli, Ayelet, and David Lane. "DayTwo: Going to Market with Gut Microbiome." Harvard Business School Case 519-010, March 2019.
- January 2018 (Revised June 2018)
- Case
Medtronic: Navigating a Shifting Healthcare Landscape
By: Robert S. Kaplan, Michael E. Porter, Thomas W. Feeley and Alee Hernandez
Medtronic is adapting its strategy to changes in healthcare competition and payments. It has decided to develop new relationships with payers, hospitals, and physicians to become more accountable for patient outcomes and total costs. The case describes new forms of... View Details
Keywords: Value Based Health Care; Bundled Payments; Health Care and Treatment; Cost Management; Value Creation; Supply Chain Management; Customer Value and Value Chain; Health Industry; Medical Devices and Supplies Industry; United States; Netherlands
Kaplan, Robert S., Michael E. Porter, Thomas W. Feeley, and Alee Hernandez. "Medtronic: Navigating a Shifting Healthcare Landscape." Harvard Business School Case 718-471, January 2018. (Revised June 2018.)
- August 2017 (Revised July 2018)
- Case
MannKind Corporation: Take a Deep Breath, This Time Afrezza Will Work
By: Elie Ofek and Amanda Dai
In June 2014, MannKind Corporation announced that after years of development and billions of dollars in expenses, the FDA had finally approved its drug, Afrezza. MannKind would thus be the only company with an inhalable insulin on the market. As an alternative to... View Details
Keywords: Health Care and Treatment; Product Launch; Product Positioning; Marketing Strategy; Adoption; Pharmaceutical Industry
Ofek, Elie, and Amanda Dai. "MannKind Corporation: Take a Deep Breath, This Time Afrezza Will Work." Harvard Business School Case 518-031, August 2017. (Revised July 2018.)
- April 2014 (Revised January 2015)
- Background Note
Note on Mobile Healthcare
By: John A. Quelch and Margaret L. Rodriguez
Delivering health care to the global population was a challenge. Health care costs accounted for ten percent of world GDP by 2013. In the U.S., health care costs were expected to top $3.1 trillion in 2014. New technologies, shortages of trained personnel and... View Details
Keywords: Health Care; Mobile; Mobile App; Public Health; Startups; Hardware; Software; Telemedicine; Global; Medical Devices; Medical Services; Medical Solutions; Entrepreneurs; Government And Business; Technological Change; Health Care and Treatment; Entrepreneurship; Government and Politics; Technological Innovation; Applications and Software; Information Infrastructure; Health Industry; Technology Industry
Quelch, John A., and Margaret L. Rodriguez. "Note on Mobile Healthcare." Harvard Business School Background Note 514-122, April 2014. (Revised January 2015.)
- November 2012
- Supplement
Amylin Pharmaceuticals (B)
By: Richard G. Hamermesh and Carin-Isabel Knoop
Amylin Pharmaceuticals brought two first-in-class diabetes drugs to market, Byetta and Symlin, in 2005, which were sold in over 80 countries with $650.7 million in sales by 2011. However, the company remained unprofitable as sales plateaued. The small pharmaceutical... View Details
Keywords: Pharmaceuticals; Bristol-Myers Squibb; Health Care and Treatment; Pharmaceutical Industry; United States
Hamermesh, Richard G., and Carin-Isabel Knoop. "Amylin Pharmaceuticals (B)." Harvard Business School Supplement 813-091, November 2012.
- January 2010
- Teaching Note
The Joslin Diabetes Center (TN)
By: Michael E. Porter, Elizabeth O. Teisberg and Scott Wallace
Teaching Note for [710424]. View Details
- October 2009 (Revised January 2010)
- Case
The Joslin Diabetes Center
By: Michael E. Porter, Elizabeth Olmsted Teisberg and Scott Wallace
The Joslin Diabetes Center in Boston, Massachusetts is a leading center for diabetes care, clinician training, and research. The incidence of diabetes is rising precipitously worldwide, challenging quality of life with its complications and rapidly accelerating health... View Details
Keywords: Integration; Service Delivery; Medical Specialties; Health Care and Treatment; Outcome or Result; Corporate Finance; Health Industry; Boston
Porter, Michael E., Elizabeth Olmsted Teisberg, and Scott Wallace. "The Joslin Diabetes Center." Harvard Business School Case 710-424, October 2009. (Revised January 2010.)
- April 2009
- Teaching Note
Amylin Pharmaceuticals: Diabetes and Beyond (TN)
By: Richard G. Hamermesh and Rachel Gordon
Teaching Note for [809011]. View Details
- December 2008 (Revised October 2013)
- Case
Amylin Pharmaceuticals: Diabetes and Beyond (A)
By: Richard G. Hamermesh and Rachel Gordon
Ginger Graham, CEO of Amylin Pharmaceuticals, joined the company with the expectation of taking the company's signature drug, Symlin, to market. However, unforeseen regulatory challenges have put the approval process in jeopardy. At the same time, the company has a... View Details
Keywords: Regulations; Drug Regulations; Symlin; Negotiation; Governing Rules, Regulations, and Reforms; Resource Allocation; Negotiation Deal; Product Development; Research and Development; Commercialization; Pharmaceutical Industry; United States
Hamermesh, Richard G., and Rachel Gordon. "Amylin Pharmaceuticals: Diabetes and Beyond (A)." Harvard Business School Case 809-011, December 2008. (Revised October 2013.)
- February 1999
- Teaching Note
Wegmans Food Markets: Diabetes Counseling TN
By: David E. Bell
Teaching Note for (9-599-057). View Details
- November 1998
- Case
Wegmans Food Markets: Diabetes Counseling
By: Ray A. Goldberg, David E. Bell and Ann Leamon
Danny Wegman, president of Wegmans Food Markets, is trying to decide how to evaluate the success of a nutrition-counseling program for diabetics, and whether and how to expand the program beyond the two stores currently involved. Wegmans, with 57 stores and $2.3... View Details
Keywords: Performance Evaluation; Expansion; Programs; Human Needs; Financial Management; Health Care and Treatment; Nutrition; Consumer Behavior; Pharmaceutical Industry; Food and Beverage Industry
Goldberg, Ray A., David E. Bell, and Ann Leamon. "Wegmans Food Markets: Diabetes Counseling." Harvard Business School Case 599-057, November 1998.